Skip to content
2000
Volume 14, Issue 21
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Chemokine receptors are a target of growing interest for new therapeutic drugs, as their role in multiple disease states has been demonstrated. The CXCR4/ CXCL12 pairing has been implicated in HIV and cancer, as well as chronic inflammatory diseases, including asthma and rheumatoid arthritis. HIV uses CXCR4 or CCR5 receptors in the key binding step of the infection process, leading to the idea that drugs could be developed to block this interaction. Cancer metastasis has also been linked to cellular communication via the chemokine pathways and hence, receptor antagonists could potentially inhibit this important pathway of disease progression. A wealth of data concerning small molecule CXCR4 receptor antagonists has been generated over the last few years, as a variety of these small molecules have been tested, and the understanding of structure activity relationships has improved. Here, we review the developing area of small molecule CXCR4 antagonists and the rapidly increasing amount of data from biological studies. Both peptidic and non-peptidic compounds have been investigated. In particular, we focus on AMD3100 and bismacrocyclic analogues, the most extensively studied class of CXCR4 antagonists, and the recent developments in this area.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/092986707781696618
2007-09-01
2025-06-07
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/092986707781696618
Loading

  • Article Type:
    Research Article
Keyword(s): AMD3100; cancer; chemokine receptors; CXCL12; CXCR4; HIV; macrocycle; metal complexes
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test